Article
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
The European respiratory journal - 1 Apr 2023
Zhang Shuzhong, Shrestha Chandra L, Robledo-Avila Frank, Jaganathan Devi, Wisniewski Benjamin L, Brown Nevian, Pham Hanh, Carey Katherine, Amer Amal O, Hall-Stoodley Luanne, McCoy Karen S, Bai Shasha, Partida-Sanchez Santiago, Kopp Benjamin T
Abstract excerpt
BACKGROUND: Abnormal macrophage function caused by dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) is a critical contributor to chronic airway infections and inflammation in people with cystic fibrosis (PWCF). Elexacaftor/tezacaftor/ivacaftor (ETI) is a new CFTR modulator therapy for PWCF. Host-pathogen and clinical responses to CFTR modulators are poorly described. We sought to determine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.